Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R56DA041201 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will determine the influence of methylphenidate (e.g., Ritalin®) and duloxetine (Cymbalta®), alone and in combination, on the cocaine use as measured by self-report and urine drug screens.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. |
|
| Duloxetine | Experimental | Subjects will be maintained on oral duloxetine. Subjects will be maintained on placebo and methylphenidate during duloxetine maintenance. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methylphenidate | Drug | The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Cocaine Positive Urines | Cocaine use will be assessed using qualitative urine drug screens over a six week period. | Six weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Self-Reported Cocaine Use | Cocaine use will be assessed using self-report on the Time Line Follow Back over a six week period. | Six weeks |
| Blood Pressure | Blood Pressure in mmHG will be measured on each week day over a six week period. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Kentucky Medical Center | Lexington | Kentucky | 40536 | United States |
Data will be shared per NIH policy. Individual participant data will not be shared.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008774 | Methylphenidate |
| D000068736 | Duloxetine Hydrochloride |
| ID | Term |
|---|---|
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine. |
|
| Duloxetine | Drug | The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate |
|
|
| Six weeks |
| Heart Rate | Heart Rate in beats per minute will be measured on each week day over a six week period. | Six weeks |
| Side effects | Subjects will complete a side effects questionnaire on each week day over a six week period. Side Effects questions will query subjects about common effects of centrally active medications. | Six weeks |
| D010880 |
| Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D013876 | Thiophenes |
| D013457 | Sulfur Compounds |